Celcuity Takes the Stage: Pivotal Cancer Drug Update Expected at Guggenheim Summit

MINNEAPOLIS, MN – February 04, 2026 – Clinical-stage biotechnology firm Celcuity Inc. is poised for a high-stakes presentation at the upcoming Guggenheim Emerging Outlook: Biotech Summit in New York, a move that has captured the attention of investors and analysts closely watching the oncology space. The company announced that CEO and Co-founder Brian Sullivan will host a fireside chat on February 11, providing a critical platform to discuss the trajectory of its lead therapeutic candidate, gedatolisib.

For a company like Celcuity (Nasdaq: CELC), which is navigating the costly and complex world of late-stage clinical trials, such events are more than just a calendar entry. They are strategic opportunities to reinforce the investment thesis, provide clarity on clinical progress, and build confidence ahead of potential data readouts and regulatory milestones. With its lead drug targeting some of the most challenging forms of breast and prostate cancer, the insights shared by Sullivan could significantly influence the company's valuation and strategic partnerships in the coming year.

A Crowded Stage of Innovators

The Guggenheim Emerging Outlook: Biotech Summit has established itself as a premier event for clinical-stage companies to connect with the institutional investors and financial analysts who can fuel their growth. Celcuity will be in the company of a diverse group of biotech innovators, each presenting its own vision for the future of medicine. Other participants scheduled for the 2026 summit include firms like Foghorn Therapeutics, Nuvalent, and enGene Holdings, all focused on cutting-edge areas from gene expression to non-viral genetic medicines and precisely targeted cancer therapies.

The presence of these peers underscores the competitive but collaborative spirit of the sector. For Celcuity, the summit provides a chance to differentiate its science and strategy. While many companies will discuss promising early-stage pipelines, Celcuity arrives with a drug, gedatolisib, already deep into Phase 3 trials—a much more advanced and de-risked position. The audience will be keen to understand how Celcuity's progress stacks up and what makes its approach unique in a field crowded with novel oncology treatments.

The Science Behind Gedatolisib

At the heart of Celcuity's story is gedatolisib, a potent inhibitor designed to blockade the PI3K/AKT/mTOR (“PAM”) pathway. This pathway is a critical signaling route that, when dysregulated, can drive the growth and proliferation of cancer cells in numerous solid tumors. While other drugs have targeted components of this pathway, gedatolisib’s potential distinction lies in its comprehensive action as a pan-PI3K and mTORC1/2 inhibitor. This dual mechanism, the company argues, provides a more complete shutdown of the cancer-promoting signals and may overcome resistance mechanisms that limit the effectiveness of other therapies.

Celcuity’s clinical development program is ambitious and focused. The flagship VIKTORIA-1 trial is a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer, a common subtype of the disease. The company has already reported results for the cohort of patients with PIK3CA wild-type tumors and has completed enrollment for the cohort with PIK3CA mutant tumors. Investors will be listening intently for any updates or timelines related to this second cohort, as positive data could pave the way for a regulatory submission.

Furthermore, the VIKTORIA-2 trial is actively enrolling patients to test gedatolisib as a first-line treatment for the same breast cancer population, potentially expanding its use to an earlier stage of disease. Beyond breast cancer, Celcuity is exploring gedatolisib's potential in metastatic castration-resistant prostate cancer through the Phase 1/2 CELC-G-201 trial, demonstrating the company’s belief in the drug’s broad applicability.

Strategic Imperatives and Investor Expectations

Brian Sullivan’s fireside chat is expected to go beyond the clinical data. Investors will be looking for a clear articulation of the company’s strategic vision. Key questions linger: What is the timeline for the final data from VIKTORIA-1? What are the next regulatory steps? And how does the company plan to navigate the complex path to commercialization, should the drug prove successful?

The competitive landscape for PI3K inhibitors has been challenging, with previous drugs in the class facing hurdles related to toxicity and efficacy. Analysts will therefore be laser-focused on any discussion of gedatolisib's safety profile and how it differentiates from competitors, both approved and investigational. Sullivan's ability to confidently address these points and outline a clear, data-driven path forward will be crucial for maintaining and growing investor support.

The presentation also serves as an important signal regarding potential partnerships. A strong showing at a venue like the Guggenheim summit can attract the attention of larger pharmaceutical companies looking to bolster their oncology pipelines. A strategic collaboration could provide Celcuity with the financial resources and global infrastructure needed for a successful product launch, mitigating the significant risks associated with going it alone.

As the date of the summit approaches, all eyes will be on Celcuity. The company stands at a pivotal juncture, with its lead asset advancing through late-stage development. The upcoming fireside chat offers a valuable window into the company's strategy and the future of a promising cancer therapy that could one day change the standard of care for thousands of patients. The messages delivered in New York will resonate long after the event, shaping the narrative for Celcuity as it moves toward its next major inflection point.